Last Updated: November 16, 2026

Investigational Drug Information for Barusiban

« Back to Dashboard


What is the drug development status for Barusiban?

Barusiban is an investigational drug.

There have been 4 clinical trials for Barusiban. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.

The most common disease conditions in clinical trials are Premature Birth, Obstetric Labor, Premature, and Infertility. The leading clinical trial sponsors are Ferring Pharmaceuticals, Tel-Aviv Sourasky Medical Center, and [disabled in preview].

Recent Clinical Trials for Barusiban
TitleSponsorPhase
Tocolytic Therapy for Preterm Labor in Multiple GestationTel-Aviv Sourasky Medical CenterPhase 3
Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine ContractionsFerring PharmaceuticalsPhase 2
Effect of Oxytocin Antagonist on Reduction of Uterine ContractionsFerring PharmaceuticalsPhase 2

See all Barusiban clinical trials

Clinical Trial Summary for Barusiban

Top disease conditions for Barusiban
Top clinical trial sponsors for Barusiban

See all Barusiban clinical trials

Barusiban Development Update and Market Projection

Last updated: November 11, 2026

Barusiban, also known as FE 200440, is an investigational selective oxytocin receptor antagonist developed primarily for the treatment of preterm labor. Public evidence indicates that clinical development did not progress to approval, commercial launch, or a late-stage registration program. The current commercial value of barusiban is therefore negligible, with market potential limited to a possible asset revival, licensing transaction, or research use.

What is the current development status of barusiban?

Barusiban is not an approved medicine and does not have an active commercial market.

Category Publicly documented status
Active ingredient Barusiban, FE 200440
Mechanism Selective oxytocin receptor antagonist
Primary indication Preterm labor
Sponsor associated with development Ferring Pharmaceuticals
Development stage reached Phase II clinical development
FDA approval None identified
EMA marketing authorization None identified
Commercial sales None identified
Orange Book listing None identified
Biosimilar relevance Not applicable
Current development status No publicly visible active development program

Barusiban was designed to block oxytocin-mediated uterine contractions. Its pharmacological rationale was similar to atosiban, an oxytocin and vasopressin receptor antagonist used in some markets for delaying preterm birth. Barusiban was intended to offer more selective oxytocin receptor activity than atosiban.

Clinical development included a randomized study in women with preterm labor. Public trial records and published reports do not show that barusiban produced a clinically competitive outcome sufficient to support regulatory filing. No subsequent pivotal Phase III program, regulatory submission, or product launch has been publicly documented. (ClinicalTrials.gov, n.d.; Ferring Pharmaceuticals, n.d.)

What clinical trials evaluated barusiban?

The principal clinical development area was threatened or established preterm labor. The intended clinical objective was to delay delivery long enough to permit administration of antenatal corticosteroids, maternal transfer to a specialist center, or other obstetric interventions.

Preterm labor program

Barusiban was studied in a controlled clinical setting involving pregnant women with preterm labor. The program evaluated whether intravenous administration could suppress uterine activity and extend pregnancy relative to comparator treatment or placebo.

The development program encountered several commercial and clinical barriers:

  1. Preterm labor is heterogeneous. Uterine contractions can result from infection, membrane rupture, cervical insufficiency, placental pathology, or other causes that are not controlled by oxytocin blockade alone.
  2. The regulatory endpoint is demanding. A reduction in contractions is less important than meaningful prolongation of pregnancy and neonatal benefit.
  3. Atosiban already provided an established pharmacological comparator in markets where oxytocin antagonism was accepted.
  4. Generic and low-cost alternatives, including magnesium sulfate and calcium-channel blockers, limited pricing potential.

The public evidence does not indicate that barusiban established superiority over atosiban or produced a sufficiently differentiated safety or efficacy profile. The absence of a disclosed Phase III program after Phase II is consistent with a discontinued or inactive development strategy, although no detailed corporate discontinuation rationale is publicly established.

When did barusiban lose exclusivity?

Barusiban has no known marketed-product exclusivity period because it was not approved by the FDA or EMA.

Exclusivity category Barusiban status
FDA new chemical entity exclusivity None
FDA orphan-drug exclusivity None identified
Pediatric exclusivity None identified
FDA qualified infectious disease exclusivity Not applicable
EMA regulatory data protection None identified
Market exclusivity from approval None
Orange Book patent term None
Commercial launch date None

A patent may have protected the compound, formulation, use, or manufacturing process during development. Patent protection does not create a commercial exclusivity period without regulatory approval and launch. Publicly available records do not establish a current, enforceable barusiban patent estate that would materially constrain a new developer.

What patents protect barusiban?

No confirmed, commercially relevant barusiban patent portfolio can be reliably identified from the public regulatory record.

The likely historical protection categories were:

  • Composition-of-matter claims covering barusiban or related oxytocin receptor antagonists.
  • Pharmaceutical composition claims covering injectable formulations.
  • Method-of-use claims for suppressing uterine contractions or treating preterm labor.
  • Manufacturing or synthetic-process claims.
  • Potential claims covering salts, stereoisomers, dosage regimens, or combinations with obstetric therapies.

Because barusiban never reached approval, the practical value of any historical patent claims is limited. Composition-of-matter patents may have expired or be approaching expiration depending on priority dates and patent-term adjustments. Later formulation and method-of-use patents would face narrower scope and potential validity challenges.

A definitive freedom-to-operate analysis would require a patent-family search across the United States, Europe, Japan, China, and other jurisdictions. The public clinical and regulatory record alone does not establish current patent expiration dates, surviving claims, terminal disclaimers, or ownership transfers.

Is barusiban listed in the FDA Orange Book?

Barusiban is not identified as an FDA-approved drug with an Orange Book listing.

The FDA Orange Book lists approved drug products and associated patents or exclusivity information. Because barusiban did not obtain FDA approval, it has no Orange Book reference listed as an approved reference listed drug. A future sponsor developing barusiban would therefore not face a conventional Abbreviated New Drug Application pathway based on an approved barusiban reference product.

A new sponsor would likely need to pursue a full 505(b)(1) application unless it could rely on another legally available regulatory pathway. A 505(b)(2) strategy could be possible if the sponsor relied on published literature or an approved comparator for portions of the clinical or pharmacological dossier, but the pathway would depend on the specific formulation, route, indication, and data package.

Are there Paragraph IV challenges involving barusiban?

No publicly established Paragraph IV litigation involving barusiban has been identified.

Paragraph IV litigation normally requires an approved reference product with listed patents in the Orange Book. Barusiban has no such approved reference product. Generic competition would therefore not emerge through a conventional Abbreviated New Drug Application challenge to a barusiban listing.

If a company revived barusiban and obtained approval, later generic entry could involve Paragraph IV certifications against any listed patents. That scenario is prospective and does not currently represent a market event.

What is the FDA regulatory status of barusiban?

Barusiban has no FDA approval, no publicly documented commercial label, and no identified U.S. marketing authorization.

The regulatory status can be summarized as follows:

Regulatory issue Status
Investigational development Yes
FDA-approved indication None
NDA approval None identified
U.S. commercial product None
FDA reference listed drug None
REMS requirement None
U.S. generic competition None
Pediatric labeling None

The absence of approval eliminates current revenue exposure but also means a new sponsor would need to reconstruct a regulatory package. Historical Phase II data could reduce early development costs, but regulators would likely require contemporary manufacturing, pharmacokinetic, safety, and efficacy evidence.

How does barusiban compare with atosiban and nolasiban?

Barusiban competes conceptually with atosiban and nolasiban, but the three assets have materially different development and commercial positions.

Drug Mechanism Main development focus Regulatory position Commercial position
Barusiban Selective oxytocin receptor antagonist Preterm labor Not approved No commercial sales
Atosiban Oxytocin and vasopressin V1a antagonist Preterm labor Approved in several non-U.S. markets Established but limited market
Nolasiban Oral oxytocin receptor antagonist Assisted reproduction and embryo implantation Development-stage asset No broad commercial market identified

Atosiban has the strongest historical commercial position because it reached approval in Europe and other jurisdictions. Its limitations include intravenous administration, restricted geographic approval, generic competition, and mixed evidence regarding neonatal and long-term clinical outcomes.

Nolasiban represents a different commercial strategy. Its oral formulation and assisted-reproduction focus could offer better outpatient convenience and higher treatment pricing than a hospital-based preterm labor product. Barusiban has no comparable current development momentum in the public record.

What market could barusiban address if development resumed?

The addressable market would be the pharmacological management of threatened preterm labor. That market is clinically significant but commercially constrained.

A revived barusiban product would face:

  • Low treatment duration, usually measured in hours or days rather than months.
  • Hospital procurement pressure.
  • Competition from inexpensive generic tocolytics.
  • Inconsistent use of tocolysis across national guidelines.
  • Limited evidence that prolonging pregnancy alone improves long-term neonatal outcomes.
  • Reimbursement sensitivity in obstetric hospital settings.
  • Need for rapid intravenous administration and inpatient monitoring.

A realistic commercial projection is therefore scenario-based:

Scenario Development assumption Estimated commercial outcome
Base case No restart of clinical development Zero product revenue
Revival case Sponsor acquires rights and conducts new Phase II/III work Limited opportunity, likely subscale before approval
Successful approval Differentiated efficacy, safety, or administration established Niche hospital product
Premium positioning Demonstrated neonatal benefit or superior tolerability Potential specialty-obstetric pricing
Generic-entry scenario Approval followed by rapid off-patent competition Short commercial window

Without a new sponsor, barusiban has no near-term market. Even with successful redevelopment, the product would likely occupy a specialist hospital niche rather than become a broad primary-care medicine.

How strong is the barusiban patent estate?

The practical strength of the barusiban patent estate appears weak for commercialization purposes.

Patent strength depends on four factors:

  1. Whether valid composition-of-matter claims remain in force.
  2. Whether claims cover the clinically useful formulation and route.
  3. Whether the original owner still controls the rights.
  4. Whether regulatory exclusivity or market recognition supports enforcement value.

Barusiban lacks the two protections that often create the strongest commercial barriers: an approved reference product and a live, differentiated clinical franchise. Historical composition claims could still be relevant in selected jurisdictions, but their value would depend on expiration dates and claim scope.

Formulation patents may offer limited protection if a new sponsor develops a novel long-acting, subcutaneous, oral, or combination formulation. Method-of-use patents could also protect a narrowly defined obstetric protocol, but such patents would not prevent competitors from using the compound for other indications or relying on alternative tocolytics.

Are there licensing deals or acquisition activity for barusiban?

No major publicly disclosed licensing transaction, acquisition, or reactivation partnership for barusiban has been identified.

Ferring Pharmaceuticals was associated with the compound's development, but public information does not establish a current commercial license, active sublicense, or announced transfer of a barusiban development program. The asset would likely be valued as a dormant clinical compound rather than as a near-term revenue-generating product.

A transaction could still be attractive if it included:

  • Access to historical clinical datasets.
  • A clean global patent position.
  • Manufacturing know-how.
  • Rights to related oxytocin receptor antagonists.
  • A reformulation suitable for assisted reproduction or outpatient obstetrics.

What generic entry risks exist for barusiban?

There is no current generic-entry risk because barusiban has no approved commercial product.

If development resumed, generic risk would arise after approval through:

  • Paragraph IV challenges to listed patents.
  • Off-label substitution by existing tocolytics.
  • Hospital formulary exclusion.
  • Competition from generic nifedipine, indomethacin, magnesium sulfate, or atosiban where available.
  • Compounded or alternative formulations.
  • Limited willingness by payers to reimburse a premium for contraction suppression without demonstrated neonatal benefit.

The largest competitive risk would not necessarily be a barusiban generic. It would be therapeutic substitution by inexpensive established medicines.

Key Takeaways

  • Barusiban, or FE 200440, is an investigational selective oxytocin receptor antagonist.
  • Its principal development target was preterm labor.
  • Public evidence supports Phase II development but no FDA or EMA approval.
  • There is no identified Orange Book listing, approved reference product, or Paragraph IV litigation.
  • No current commercial revenue or established market share exists.
  • The patent position may have had historical composition, formulation, and method-of-use coverage, but its present commercial strength is not established.
  • A revival would require substantial regulatory and clinical investment.
  • The most realistic commercial outcome is a niche hospital product, not a broad blockbuster.
  • Current base-case market revenue is zero because the product is not marketed.

FAQs About Barusiban Development and Commercial Potential

Is barusiban the same as atosiban?

No. Both are oxytocin receptor antagonists developed for preterm labor, but atosiban also antagonizes the vasopressin V1a receptor and reached approval in several markets. Barusiban remained investigational.

Can barusiban still be developed?

Yes, in principle, but a sponsor would need to establish current intellectual-property rights, update manufacturing data, and generate clinical evidence acceptable to regulators. No active redevelopment program is publicly established.

Does barusiban have orphan-drug exclusivity?

No publicly documented FDA or EMA orphan-drug exclusivity exists for barusiban.

Could barusiban be used in IVF?

Oxytocin receptor antagonism has been explored in assisted reproduction, but barusiban's publicly established development focus was preterm labor. No approved IVF indication exists.

What is the investment case for barusiban?

The asset has low near-term value because it has no approval, sales, regulatory exclusivity, or confirmed active sponsor. Its potential value would depend on a low-cost revival strategy, differentiated formulation, or new clinical positioning supported by defensible intellectual property.

References

  1. ClinicalTrials.gov. (n.d.). Clinical studies involving barusiban and preterm labor. U.S. National Library of Medicine. https://clinicaltrials.gov/

  2. Ferring Pharmaceuticals. (n.d.). Research and development information. https://www.ferring.com/

  3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

  5. European Medicines Agency. (n.d.). Medicines database and European public assessment reports. https://www.ema.europa.eu/en/medicines

  6. World Health Organization. (n.d.). WHO recommendations for prevention and treatment of preterm birth. https://www.who.int/ Reproductive Health.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.